UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000037710
Receipt number R000043011
Scientific Title The significance of Hypertriglyceridemia in life-style diseases
Date of disclosure of the study information 2019/08/17
Last modified on 2023/08/20 11:15:58

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The significance of Hypertriglyceridemia in life-style diseases

Acronym

TG-rich study

Scientific Title

The significance of Hypertriglyceridemia in life-style diseases

Scientific Title:Acronym

TG-rich study

Region

Japan


Condition

Condition

Metabolic syndrome, obesity, diabetes, hypertension, chronic kidney disease (CKD)

Classification by specialty

Medicine in general Endocrinology and Metabolism Nephrology

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

Diagnosis and classification of dyslipidemia associated with various life-style diseases and exploratory research for the elucidation of molecular mechanism for the progression of atherosclerosis.

Basic objectives2

Others

Basic objectives -Others

Identification of disease mechanism for the development of dyslipidemia and atherosclerosis.

Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

1. Diagnosis and classification of dyslipidemia.
2. Identification of mutations for the known responsible genes for the development of dyslipidemia such as LPL. APOC2, APOC3, APOA5, LMF1, GPIHBP1, GCKR, CREB3L3, GPD1.
(Since the current study is cross-sectional clinical study, there is no observation period.)

Key secondary outcomes

1. Measurement of HMGB1, HRG, mir-221/222, mir-335, mir-342 in serum and plasma samples.
2. Identification of unknown causal genes for development of dyslipidemia.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

No need to know


Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Gene Other

Interventions/Control_1

Measurement of MGB1, HRG, microRNAs (mir-221/222, mir-335, mir-342) in serum and plasma samples, and identification of mutations in dyslipidemia-related known genes such as LPL. APOC2, APOC3, APOA5, LMF1, GPIHBP1, GCKR, CREB3L3, GPD1, and other unknown genes.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

The patients with metabolic syndrome, obesity, diabetes, hypertension and chronic kidney disease (CKD), who agree the paticipation in the investigation. The patients will be enrolled regardless of age, gender, out-patient and in-patient.

Key exclusion criteria

The patients who are judged as inappropriate for the study and who disagree the enrollment.

Target sample size

300


Research contact person

Name of lead principal investigator

1st name Jun
Middle name
Last name Wada

Organization

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Division name

Department of Nephrology, Rheumatology, Endocrinology and Metabolism

Zip code

700-8558

Address

2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan

TEL

086-235-7232

Email

junwada@okayama-u.ac.jp


Public contact

Name of contact person

1st name Naoko
Middle name
Last name Kurooka

Organization

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Division name

Department of Nephrology, Rheumatology, Endocrinology and Metabolism

Zip code

700-8558

Address

2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan

TEL

086-235-7235

Homepage URL


Email

shiropanda34@gmail.com


Sponsor or person

Institute

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of Nephrology, Rheumatology, Endocrinology and Metabolism

Institute

Department

Personal name



Funding Source

Organization

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of Nephrology, Rheumatology, Endocrinology and Metabolism

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital, Ethics Committee

Address

2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan

Tel

086-235-6938

Email

mae6605@adm.okayama-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 08 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2019 Year 07 Month 05 Day

Date of IRB

2019 Year 07 Month 05 Day

Anticipated trial start date

2019 Year 08 Month 17 Day

Last follow-up date

2026 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 08 Month 17 Day

Last modified on

2023 Year 08 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043011


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name